Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.
Chief Executive Officer Bernard Zovighian said the
As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a "steady Eddie" of the MedTech world that provided everything from basic syringes to complex diagnostic laboratory equipment. However, the recent completion of the Biosciences [...]
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
The U.S. mergers and acquisitions (M&A) landscape has entered a definitive new era in early 2026, marked by what analysts are calling a "Strategic Rebound." After years of aggressive antitrust intervention and a "litigation-first" posture from federal regulators, the tide has turned toward regulatory pragmatism. Large-cap companies, once
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
